Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
First-Ever U.S. Patent Challenges Dispute Gilead’s Monopoly on Hepatitis C Drugs that Blocks Millions from Treatment
Under-the-radar SCOTUS patent case could have big implications for drug prices, access
Patents, Licenses and Drug Prices
Supreme Court Case Could Threaten America’s Ability to Lower Exorbitant Drug Prices, New Policy Brief Warns
DEEP DIVE OPINION: Increasing access to medicines: A critical look at pharmaceutical patents
Patently Dumb: America’s current patent system inhibits innovation. Here’s how to fix it
Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries
AbbVie’s New Hepatitis C Treatment Won’t Cure Patient Access Issue
WHO moves to widen access to generic Sovaldi in dozens of countries
After India, I-MAK files legal challenge against Gilead’s hepatitis C drug sofosbuvir in China